Life Sciences

Akili Interactive Stock for Digital Therapeutics

Regular readers of Nanalyze may have noticed that we don’t cover too many startups these days. That’s partly because you’ve let us know that you’re most interested in learning about investment opportunities available to retail investors. Many people who invest in private companies are folks who shower in the morning and don’t have to pull […]

Butterfly Network Stock: On Sale Now At a 40% Discount

“Wait for the dust to settle. If shares start to approach the $10 mark, then you’ll be paying what the smart money paid.” That’s what we said about Butterfly Network (BFLY) back in November 2020 when they decided to go public using a special purpose acquisition company (SPAC). Seems like the smart money overpaid as […]

UTHR Stock and the Xenotransplantation Thesis

Oftentimes, we’ll come across a promising investment thesis that’s sailed through most of its life without accomplishing much. (Graphene anyone?) While some investors bet on carbon-based nanomaterials transforming the entire materials industry, others looked to new engine designs that might disrupt the automotive industry. We’ve covered at least half a dozen companies trying to reinvent […]

SomaLogic Stock: A Significant First-Mover Advantage?

Proteomics – the study of proteins – is incredibly complex stuff. That’s why fund managers often hire subject matter experts to navigate such topics. We disagree with this approach. You cannot invest in what you know if you need an interpreter to do so. A simple understanding of the opportunity can suffice in most cases. […]

Sonendo Stock: Dental Technology for Root Canal Therapy

Plenty of people talk about how they hate going to the dentist, but apparently, dentophobia is a real thing. One study found that nearly a quarter of people feared the dentist chair, while dentophobia was the most common among 10 different phobias (defined as excessive fear or anxiety) at 3.7% – even more than fear […]

Myriad Genetics Stock vs. Invitae Stock

If you stick your neck out and make a long-term call on a stock that turns out to be right, expect to hear nothing but crickets years later when you’re proven right. If your call turns out to be wrong, people will be lining up around the block to point out what an idiotic buffoon […]

Definitive Healthcare Stock: Commercial Intelligence SaaS

It’s easy to understand why the market assigns a premium to software-as-a–service (SaaS) business models. Typically, such companies have a broad customer base with no single customer accounting for more than a small fraction of revenues. They’re usually high-growth companies where the more customers brought on board, the higher the margins. And most importantly, they […]

What’s Up With Illumina’s Acquisition of GRAIL?

If you want to land a job at a top investment bank, there’s an expectation that you’ve read certain material. Even though prop trading desks have gone the way of the dodo, books like Liar’s Poker and Reminiscences of a Stock Operator are must-reads. So is the 592-page monster, Barbarians at the Gate, a glimpse […]

Oxford Nanopore Stock: The Internet of Living Things

If you took all the stocks in the world and put them in a single basket, about 58% of that combined market cap would be U.S. stocks. If you want to look that number up, just download a fact sheet for the MSCI ACWI IMI Index. All those cryptic acronyms mean that the index includes […]

Cellect Biotechnology Stock: Surviving, Not Thriving

Fear of missing out, FOMO, is the bane of every newbie investor who sees rapid short-term price appreciation as a good thing. When a stock doubles in a single trading session, that’s the type of volatility risk-averse investors try to avoid. It’s precisely why we don’t invest in drug developers – life sciences companies with […]